Systhesis, Characterization and Spectroscopic Properties of (2E,6E)-2,6-Bis(2,3,4-tri-methoxy-benzylidene)cyclohexanone

Abstract:

In this paper, (2E,6E)-2,6-Bis(2,3,4-tri-methoxy -benzylidene)cyclohexanone (omitted as tmbcho) (1) was obtained by the reaction of acetic acid, tetrahydrofuran, cyclohexanone and 2,3,4-tri-methoxy-benzaldehyde. Three non-classic hydrogen bonds were observed in the compound. X-ray crystallography shows that the crystal structure is stabilized by intermolecular C-H•••π interactions and it contains plenty of conjugated double bonds. The title compound was characterized by UV-vis and fluorescent spectral studies.

• Periodical: Advanced Materials Research (Volumes 396-398)
• Pages: 2338-2341
• DOI: https://doi.org/10.4028/www.scientific.net/AMR.396-398.2338
• Online since: November 2011
• Authors: Xing Chuan Wei, Zhi Li Liu, Kun Zhang, Zhi Yun Du, Xi Zheng
• Keywords: Curcumin Analogues, Raman Spectra, Systhesis, Thermogravimetric

References

[1] B. B. Aggarwal, B. Sung, Trends Pharmacol. Sci. Vol. 30 (2009), p.85

[2] R. Kuttan, P. Bhanumathy, K. Nirmala, M. C. George, Cancer Lett. Vol. 29 (1985), p.197

[3] M-T. Huang, R. C. Smart, C-Q. Wong, A. H. Conney, Cancer Res. Vol. 48 (1988), p.5941

[4] M-T. Huang, Z. Y. Wang, C. A. Georgiadis, J. D. Laskin, A. H. Conney, Carcinogenesis 13 (1992), p.2183

[5] M-T. Huang, Y-R. Lou, W. Ma, H. L. Newmark, K. R. Reuhl, A. H. Conney, Cancer Res. Vol. 54 (1994), p.5841

[6] C. V. Rao, A. Rivenson, B. Simi, B. Reddy, Cancer Res. Vol. 55 (1995), p.259

[7] P. Anand, A. B. Kunnumakkara, R. A. Newman, B. B. Aggarwal, Mol. Pharm. Vol. 4 (2007), p.807

[8] B. K. Adams, E. M. Ferstl, M. C. Davis, M. Herold, S. Kurtkaya, R. F. Camalier, M. G. Hollingshead, G. Kaur, E. A. Sausville, F. R. Rickles, J. P. Snyder, D. C. Liotta, M. Shoji, Bioorg. Med. Chem. Vol. 12 (2004), p.3871

DOI: 10.1016/j.bmc.2004.05.006

[9] K. H. Lee, F. H. Ab Aziz, A. Syahida, F. Abas, K. Shaari, D. A. Israf, N. H. Lajis, Eur. J. Med. Chem. Vol. 44 (2009), p.3195

[10] C. Zhao, J. Yang, Y. Wang, D. Liang, X. Yang, X. Li, J. Wu, X. Wu, S. Yang, X. Li, G. Liang, Bioorg. Med. Chem. Vol. 18 (2010), p.2388

[11] B. Yadav, S. Taurin, R. J. Rosengren, M. Schumacher, M. Diederich, T. J. Somers-Edgar, L. Larsen, Bioorg. Med. Chem. Vol. 18 (2010), p.6701

DOI: 10.1016/j.bmc.2010.07.063

[12] A. Sun, M. Shoji, Y. J. Lu, D. C. Liotta, J. P. Snyder, J, Med, Chem. Vol. 49 (2006), p.3153

[13] T. J. Somers-Edgar, S. Taurin, L. Larsen, A. Chandramouli, M. A. Nelson, R. Rosengren, J. Invest. New Drugs. Vol. 29 (2011), p.87

DOI: 10.1007/s10637-009-9339-0

[14] T. P. Robinson, T. Ehlers, R. B. Hubbard IV, X. Bai, J. L. Arbiser, D. J. Goldsmith, J. P. Bowen, Bioorg. Med. Chem. Lett. Vol. 13 (2003), p.115

[15] H. Ohori, H. Yamakoshi, M. Tomizawa, M. Shibuya, Y. Kakudo, A. Takahashi, S. Takahashi, S. Kato, T. Suzuki, C. Ishioka, Y. Iwabuchi, H. Shibata, Mol. Cancer Ther. Vol. 5 (2006), p.2563

DOI: 10.1158/1535-7163.mct-06-0174

[16] D. Subramaniam, R. May, S. M. Sureban, K. B. Lee, R. George, P. Kuppusamy, R. P. Ramanujam, K. Hideg, B. K. Dieckgraefe, C. W. Houchen, S. Anant, Cancer Res. Vol. 68 (2008), p. (1962)

DOI: 10.1158/0008-5472.can-07-6011

[17] G. Liang, L. Shao, Y. Wang, C. Zhao, Y. Chu, J. Xiao, Y. Zhao, X. Li, S. Yang, Bioorg. Med. Chem. Vol. 17 (2009), p.2623

[18] K. M. Youssef, M. A. El-Sherbeny, F. S. El-Shafie, H. A. Farag, O. A. Al-Deeb, S. A. Awadalla, A. Arch. Pharm. Pharm. Med. Chem., Vol. 337(2004), 42-54.

DOI: 10.1002/ardp.200300763

[19] S. S. Sardjiman, M. S. Reksohadiprodjo, L. Hakim, H. Van der Goot, H. Timmerman, Eur. J. Med. Chem., Vol. 32 (1997), p.625